EpiVax launches EpiVax Oncology for personalized cancer vaccines

EPIVAX PRESIDENT AND CEO Dr. Anne S. De Groot. EpiVax has launched a venture-backed spinoff, Epivax Oncology. / PBN FILE PHOTO
EPIVAX PRESIDENT AND CEO Dr. Anne S. De Groot. EpiVax has launched a venture-backed spinoff, Epivax Oncology. / PBN FILE PHOTO
PROVIDENCE — Immunolgy engineering biotech firm EpiVax Inc. has launched EpiVax Oncology Inc., a venture-backed spinoff focused on the development of personalized therapeutic cancer vaccines. EpiVax Oncology, an independent company, is conducting a $2 million bridge capital raise to prepare for an Investigational New Drug application as well as a $10 million to $25 million…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -